佳礼资讯网

 找回密码
 注册

ADVERTISEMENT

楼主: 留下眼镜

【CCM 2879 交流专区】马化工

  [复制链接]
发表于 17-1-2010 12:02 PM | 显示全部楼层
现在 2.2X 值得买吗 ?
回复

使用道具 举报


ADVERTISEMENT

发表于 20-8-2011 07:14 PM | 显示全部楼层
马化工次季净利飙2倍

财经新闻 财经  2011-08-20 11:09
(吉隆坡19日讯)受化学与制药业高盈利赚幅激励,马化工(CCM,2879,主板工业产品股)截至6月30日财年次季,净利飙涨2.3倍至659万7000令吉,上财年录得199万6000令吉。

单季营业额相反,由上财年4亿2297万8000令吉跌1.79%至4亿1542万3000令吉。

马化工首6个月净利报1279万7000令吉,较上财年的284万2000令吉劲扬了3.5倍。

该公司合计两季的营业额则为8亿1311万1000令吉,上财年录得7亿9166万1000令吉,按年增长2.71%。

尽管全球经济因美国信贷评级下调和欧债危机而不稳定,加上原棕油、氢氧化钠(caustic soda)以及其他原产品价格将呈下跌趋势,但马化工仍对此保持谨慎乐观看待全球经济局势。

马化工预计,主要市场如大马、印尼和新加坡料将取得正面的国内生产总值(GDP)增长率。[NanYang]
回复

使用道具 举报

发表于 24-11-2011 01:08 AM | 显示全部楼层
马化工第三季净利挫99%

财经新闻 财经  2011-11-23 12:30
(吉隆坡22日讯)马化工(CCM,2879,主板工业产品股)2011财年第三季净利、从上财年的1460万8000令吉,下跌99.89%至1万6000令吉。

前盈利也从上财年同期的的2350万令吉,下跌45.1%至1290万令吉,主要因为化肥业务低收入影响。

马化工营业额则上扬1.5%至3亿9427万2000令吉,高于上财年同期的3亿8837万3000令吉。

集团累积首九个月净利下跌26.57%至1281万3000令吉,营业额增长2.3%至12亿738万3000令吉。

受益于化学和医疗保健业务的高赚幅,马化工税前盈利则从上财年4020万令吉,增长18.9%至4780万令吉。[NanYang]
回复

使用道具 举报

发表于 2-3-2012 02:10 AM | 显示全部楼层

SUMMARY OF KEY FINANCIAL INFORMATION

31/12/2011



INDIVIDUAL PERIOD

CUMULATIVE PERIOD

CURRENT YEAR QUARTER

PRECEDING YEAR
CORRESPONDING
QUARTER

CURRENT YEAR TO DATE

PRECEDING YEAR
CORRESPONDING
PERIOD

31/12/2011

31/12/2010

31/12/2011

31/12/2010

$$'000

$$'000

$$'000

$$'000

1Revenue

402,761

459,000

1,610,144

1,639,039

2Profit/(loss) before tax

10,661

18,952

58,449

59,200

3Profit/(loss) for the period

13,771

7,315

39,313

33,071

4Profit/(loss) attributable to ordinary equity holders of the parent

8,829

-2,078

21,642

15,372

5Basic earnings/(loss) per share (Subunit)

2.18

-0.51

5.35

3.80

6Proposed/Declared dividend per share (Subunit)

2.75

2.65

2.75

2.65









AS AT END OF CURRENT QUARTER

AS AT PRECEDING FINANCIAL YEAR END

7
Net assets per share attributable to ordinary equity holders of the parent ($$)

1.8400

1.8700

回复

使用道具 举报

发表于 9-4-2012 10:45 PM | 显示全部楼层
Company Name

:

CHEMICAL COMPANY OF MALAYSIA BERHAD
Stock Name

:

CCM  
Date Announced

:

09/04/2012

EX-date

:

29/06/2012
Entitlement date

:

03/07/2012
Entitlement time

:

04:00:00 PM
Entitlement subject

:

Final Dividend
Entitlement description

:

Final Dividend of 2.86 sen per ordinary share comprising the following:

a) Gross Final Dividend of 0.44 sen per ordinary share (less 25% tax); and
b) Final Tax Exempt Dividend of 2.42 sen per ordinary share.
Period of interest payment

:

to
Financial Year End

:

31/12/2011
Share transfer book & register of members will be

:

to closed from (both dates inclusive) for the purpose of determining the entitlements
Registrar's name ,address, telephone no

:

Symphony Share Registrars Sdn Bhd
Level 6, Symphony House
Block D13, Pusat Dagangan Dana 1
Jalan PJU 1A/ 46
47301 Petaling Jaya
Selangor Darul Ehsan
Telephone No: 03-78418000
Payment date

:

24/07/2012

a.

Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers

:

03/07/2012

b.

Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit

:

29/06/2012

c.

Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)

:

Entitlement indicator

:

Currency
Currency

:

Malaysian Ringgit (MYR)
Entitlement in Currency

:

0.0286

Remarks :
The Final Dividend of 2.86 sen per ordinary share comprising of Gross Final Dividend of 0.44 sen per ordinary share (less 25% tax) and Final Tax Exempt Dividend of 2.42 sen per ordinary share, is subject to shareholders' approval at the forthcoming Annual General Meeting of the Company.
回复

使用道具 举报

发表于 3-5-2012 09:29 AM | 显示全部楼层
馬化工獲1.1億中期貸款

財經02/05/2012 22:30
(吉隆坡2日訊)馬化工(CCM,2879,主要板工業)獲得三菱東京日聯銀行(Bank of Tokyo-Mitsubishi UFJ)提供總值1億1000萬令吉的中期貸款。

馬證交所報備指出,上述以美元計價的中期貸款,是該公司重組所有短期債務至中期的一部分。

總值1億1000萬令吉的中期貸款屆滿期為2015年4月30日,為期3年,馬化工主要是為其週轉信貸便利進行再融資。[ChinaPress]
回复

使用道具 举报

Follow Us
发表于 22-5-2012 02:20 AM | 显示全部楼层

SUMMARY OF KEY FINANCIAL INFORMATION

31/03/2012



INDIVIDUAL PERIOD

CUMULATIVE PERIOD

CURRENT YEAR QUARTER

PRECEDING YEAR
CORRESPONDING
QUARTER

CURRENT YEAR TO DATE

PRECEDING YEAR
CORRESPONDING
PERIOD

31/03/2012

31/03/2011

31/03/2012

31/03/2011

$$'000

$$'000

$$'000

$$'000

1Revenue

357,878

397,688

357,878

397,688

2Profit/(loss) before tax

15,957

14,570

15,957

14,570

3Profit/(loss) for the period

10,312

9,194

10,312

9,194

4Profit/(loss) attributable to ordinary equity holders of the parent

6,725

6,200

6,725

6,200

5Basic earnings/(loss) per share (Subunit)

1.66

1.53

1.66

1.53

6Proposed/Declared dividend per share (Subunit)

0.00

0.00

0.00

0.00









AS AT END OF CURRENT QUARTER

AS AT PRECEDING FINANCIAL YEAR END

7
Net assets per share attributable to ordinary equity holders of the parent ($$)

1.8700

1.8500

回复

使用道具 举报

发表于 27-5-2012 12:04 AM | 显示全部楼层
与跨国公司合作 马化工拓展药业

财经新闻 财经  2012-05-26 11:32
(巴生25日讯)马化工(CCM,2879,主板工业产品股)冀望趁创新专利(Innovator Patents)期届满,透过与跨国制药公司的合作,扩展通用畅销药物的业务。

马化工主席丹斯里阿布巴卡表示,未来10年创新畅销药物料已不受专利权束缚,预计每年销量将达4350亿令吉。

“对通用药物制造商来说,这是好机会,马化工放眼扩展创新通用畅销药物业务。”

他是在昨日举行的常年股东大会后,透过文告发表上述言论。

随着创新专利期届满,继而推动制造领域的发展潜能,阿布巴卡因而乐观看待公司的未来业务发展前景。

“我们认为,现阶段极具扩展新市场和延伸产品潜能,马化工可藉此推动业务增长。”

营业额增5%
制药公司的创新专利期届满后,公司将面临“专利悬崖”(Patent Cliff)的情况。“专利悬崖”是指制药专利权到期后,依靠专利权获取销售额和利润的公司就会一落千丈的情况。

截至去年12月杪财年,马化工营业额共计1亿3813万令吉,较2010财年1亿3144万令吉增加5.1%。[Nanyang]
回复

使用道具 举报


ADVERTISEMENT

发表于 28-6-2012 03:44 PM | 显示全部楼层
马化工系列策略维持增长

财经新闻 财经  2012-06-28 11:41
(吉隆坡27日讯)马化工(CCM,2879,主板工业产品股)将透过系列策略计划来维持市场增长,以及改善化学、制药和肥料业务的盈利表现。

马化工指出,上述策略计划包括化学和制药业务会专注高赚幅产品、选择性进行区域扩展和研发活动,肥料业务则会以发展新产品为焦点。

马化工集团董事经理阿米鲁费沙今日出席该公司股东常年大会后表示,他乐观于复兴市场动力,同时会维持不断开拓任何可能性的精神,以及让公司产品达致世界级的标准。

他指出,化学业务在2011年的业务合理化策略,包括专注发展氯碱(chlor-alkali)和聚合物业务,促使它成为集团去年表现最优越的业务。

因此,马化工欲继续透过发展其核心强项来扩展业务,如化学业务将以水和橡胶化学为焦点、制药业务会依赖其非处方药(OTC)产品和清真认证,肥料业务则会专注透过高素质和合成肥料定制方式为客户塑造更多价值。[Nanyang]
回复

使用道具 举报

发表于 17-8-2012 08:57 PM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30/06/2012
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30/06/2012
30/06/2011
30/06/2012
30/06/2011
$$'000
$$'000
$$'000
$$'000
1Revenue
403,095
415,423
760,973
813,111
2Profit/(loss) before tax
10,722
20,346
26,679
34,916
3Profit/(loss) for the period
8,086
11,920
18,398
21,114
4Profit/(loss) attributable to ordinary equity holders of the parent
3,060
6,597
9,785
12,797
5Basic earnings/(loss) per share (Subunit)
0.76
1.63
2.42
3.16
6Proposed/Declared dividend per share (Subunit)
0.00
0.00
0.00
0.00


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.8700
1.8500

回复

使用道具 举报

发表于 23-8-2012 07:40 PM | 显示全部楼层
馬化學3大業務表現如何?

投資致富  2012-08-23 15:09

麻木友問:
馬化學(CCM,2879,主板工業產品組)還值得投資嗎?最近股息好像給得很少。至於3大核心業務,即化學、藥劑及肥料表現如何?最近幾年,肥料及化學業務投資了上億令吉新廠房及設備,但好像付諸東流,尤其是肥料業務傳出高層更替,請代查明。

答:
馬化學截至3月31日首季取得672萬5千令吉淨利,較前期揚升8.47%,歸功於盈利賺幅從14%提昇至19%。
2011年全年淨利則彈升40.79%至2千164萬2千令吉。

雖然化學業務稅前盈利下滑15%至760萬令吉,不過其盈利賺幅卻從18%提高至21%;藥劑業務從政府合約中受惠,激勵稅前盈利大增78%至750萬令吉。

肥料業務銷售跌成本漲
至於肥料業務卻因銷售下跌而導致表現有欠理想,稅前盈利走跌26%至230萬令吉,而去年全年則滑跌10%,成為唯一蒙虧的業務。

同時,原料成本上漲令賺幅收窄,也是肥料業務走勢低迷的因素之一。

馬化學指出,新廠房須時釋放效益,以長遠目標為主,並展開各種資本開銷計劃,以加強產能與效率,提高競爭力與領域定位。該公司鎖定未來數年進軍新市場,如中東國家,以推動藥劑業的成長。

積極尋求區域併購
基於本地市場小,該公司正積極尋求潛在區域併購計劃,以開拓更大市場,特別是印尼、泰國及越南。馬化學藥業(CCMDBIO,7148,主板消費品組)現有總產能不大,因此相信必須透過海外市場來達到理想產能。

根據最新的年報,馬化學的肥料業務並沒有出現管理層變動,依然由馬末出任肥料業務董事。

另外,市場一直傳出馬化學有意將股票流通率低企的馬化學藥業私有化,以改善股東價值,惟該公司都沒有作出正面回應。(星洲日報/投資致富‧投資問診室)
回复

使用道具 举报

发表于 23-11-2012 10:28 PM | 显示全部楼层
CHEMICAL COMPANY OF MALAYSIA BERHAD

Type of Securities
Warrants
Type of Expiry
Expiry/Maturity of the securities
Mode of Satisfaction of Exercise/Conversion Price
Cash
Exercise/Strike/Conversion Price
MYR 1.3600
Exercise/ Conversion Ratio
1:1
Settlement Type/ Convertible into
Physical (Shares)
Last Date & Time for Trading
07/12/2012 05:00 PM
Date & Time of Suspension
10/12/2012 09:00 AM
Last Date & Time for Transfer into Depositor's CDS a/c
18/12/2012 04:00 PM
Date & Time of Expiry
26/12/2012 05:00 PM
Date & Time of Delisting
27/12/2012 09:00 AM


回复

使用道具 举报

发表于 24-11-2012 12:52 AM | 显示全部楼层
SUMMARY OF KEY FINANCIAL INFORMATION
30/09/2012
INDIVIDUAL PERIOD
CUMULATIVE PERIOD
CURRENT YEAR QUARTER
PRECEDING YEAR
CORRESPONDING
QUARTER
CURRENT YEAR TO DATE
PRECEDING YEAR
CORRESPONDING
PERIOD
30/09/2012
30/09/2011
30/09/2012
30/09/2011
$$'000
$$'000
$$'000
$$'000
1Revenue
374,049
394,272
1,135,022
1,207,383
2Profit/(loss) before tax
14,697
12,872
41,376
47,788
3Profit/(loss) for the period
11,708
4,429
30,106
25,542
4Profit/(loss) attributable to ordinary equity holders of the parent
8,222
17
18,007
12,813
5Basic earnings/(loss) per share (Subunit)
2.03
0.00
4.45
3.17
6Proposed/Declared dividend per share (Subunit)
0.00
0.00
0.00
0.00


AS AT END OF CURRENT QUARTER
AS AT PRECEDING FINANCIAL YEAR END
7
Net assets per share attributable to ordinary equity holders of the parent ($$)
1.8600
1.8500

回复

使用道具 举报

发表于 19-12-2012 02:36 PM | 显示全部楼层
获印度Biocon 独家经销权 马化工大马汶莱售胰岛素产品

财经新闻 财经  2012-12-19 11:33
(吉隆坡18日讯)马化工(CCM,2879,主板工业产品股)独资子公司CCM药剂私人有限公司(CCMP)获印度Biocon有限公司颁布独家经销权,在大马和汶莱经销一系列胰岛素产品。

配合上述合作,CCMP今日与Biocon旗下瑞士Biocon SA签署独家执照协议,也与Biocon和Biocon大马私人有限公司签署供应及经销胰岛素产品协议。

马化工集团董事经理阿米鲁费沙和Biocon财务总裁慕拉里克里斯南、在卫生部长拿督斯里廖中莱的见证下交换协议。

双方预计,此合作会将大马和汶莱的胰岛素市值提高至约9000万令吉。

抢攻市占
阿米鲁费沙表示,这合作符合马化工的业务方针,即透过建立策略合作关系加强药剂业务在独特医疗领域(如肿瘤科、生技仿制药剂和疫苗)的产品组合。

阿米鲁费沙说:“与全球主要业者如Biocon合作打造我们的生技仿制药剂产品组合,除了可具体剌激和加强我们在开发非专利药剂方面的能力,也让我们能在创新产品专利权过期之际行销。”

“糖尿病迅速达到如流行病般的程度,所有国家都受这种长期内会影响社会及人类发展的疾病冲击。”

他补充,CCMP所推出的抗糖尿病产品、加上Biocon胰岛素系列产品,有望争取到糖尿病药剂市场更大的市占率。[Nanyang]
回复

使用道具 举报

发表于 21-12-2012 10:58 PM | 显示全部楼层
CHEMICAL COMPANY OF MALAYSIA BERHAD

Type
Announcement
Subject
OTHERS
Description
Term Loan Facility amounting to RM200.0 million equivalent in USD from The Bank of Tokyo – Mitsubishi UFJ, Ltd.
1. INTRODUCTION
The Board of Directors of Chemical Company of Malaysia Berhad (“CCM” or “the Company”) wishes to announce that the Company has entered into an agreement to execute the drawdown with Bank of Tokyo – Mitsubishi UFJ, Ltd. (the “Bank”) for a Cross Currency Swap amounting to RM200 million equivalent in USD (based on prevailing market rate at the time of execution of the transaction) upon the terms and conditions contained in the Bank’s offer letter.
  
2. RATIONALE FOR THE TERM LOAN FACILITY
The Facility is part of the Group’s financing plan to restructure its current borrowingstenure from short term to mid term. The Facility has two tenure, of which RM50 million will be expiring on 29 December 2014 and RM150 million expiring on 21 December 2015. The proceeds from the Facility will be used to refinance its Cross Currency Swap maturity totaling the same amount.

3. INFORMATION ON CHEMICAL COMPANY OF MALAYSIA BERHAD
CCM was incorporated in Malaysia on 7 August 1963 under the Companies Ordinance, 1940-1946 under the name of Chemical Company of Malaysia Limited. On 15 April 1966, CCM assumed its present name. It was listed on the Main Board of Bursa Securities on 24 March 1966 and having its registered address at 13th Floor, Menara PNB, 201-A Jalan Tun Razak, 50400 Kuala Lumpur.
CCM is an investment holding and management company with subsidiaries and an associate company engaged in the manufacturing, marketing and/ or supply of fertilizers, chemicals and pharmaceuticals products and services.
  
4. FINANCIAL EFFECT OF THE TERM LOAN FACILITY
(a) Share Capital
The Facility will not have any effect on the share capital of the Company and the shareholding of the substantial shareholders of the Company.
(b) Net Assets
The Facility will not have any material effect on the net assets of the CCM Group for the financial year ending 31 December 2012.

(c) Earnings
The Facility will not have any material effect on the earnings of the CCM Group for the financial year ending 31 December 2012.

(d) Utilisation of Proceeds
The Facility is to refinance the Group’s existing borrowings, namely the Cross Currency Swap facilities.


5. INTERESTS OF DIRECTORS, MAJOR SHAREHOLDERS AND PERSONS CONNECTED
None of the Directors and/or substantial shareholders of CCM and persons connected have any interest, direct or indirect, in the Facility.

6. DIRECTORS’ RECOMMENDATION
The Board, after careful deliberation, is of the opinion that acceptance of the Facility is in the best interest of the Company and CCM Group.

7. APPROVAL REQUIRED
CCM has obtained Bank Negara Malaysia approval for the abovementioned Facility.


8. DOCUMENTS FOR INSPECTION
The relevant agreements in relation to the Facility are available for inspection at the Registered Office of the Company at 13th Floor, Menara PNB, 201-A Jalan Tun Razak, 50400 Kuala Lumpur during normal office hours for a period of one month from the date of this announcement.

This announcement is dated 21 December 2012.



回复

使用道具 举报

发表于 26-12-2012 12:51 PM | 显示全部楼层
为什么EPF近两个月频频抛售股票?
难道有问题吗?为什么没有任何消息的?
回复

使用道具 举报


ADVERTISEMENT

发表于 26-12-2012 10:03 PM | 显示全部楼层
Notice of Person Ceasing (29C)
CHEMICAL COMPANY OF MALAYSIA BERHAD

Particulars of substantial Securities Holder
NamePERMODALAN NASIONAL BERHAD
AddressTINGKAT 4, BALAI PNB
201-A, JALAN TUN RAZAK
50400 KUALA LUMPUR
NRIC/Passport No/Company No.038218X
Nationality/Country of incorporationBUMIPUTERA-OWNED COMPANY
Descriptions (Class & nominal value)WARRANTS B
Date of cessation18/12/2012
Name & address of registered holderPERMODALAN NASIONAL BERHAD
TINGKAT 4, BALAI PNB
201-A, JALAN TUN RAZAK
50400 KUALA LUMPUR
CurrencyMalaysian Ringgit (MYR)
Number of securities disposed52,821,503
Price Transacted ($$)
Circumstances by reason of which a person ceases to be a substantial securities HolderSale of Shares
Nature of interestDirect
Date of notice18/12/2012

Remarks :
Permodalan Nasional Berhad has subscribed 52,821,503 units of Warrants B which expires on 26 December 2012 at an Exercise Price of RM1.36 for each new share and therefore, ceased to be a Substantial Warrantholder.

The Notice on the above was received by the Company Secretarial Department on 26 December 2012.



Announcement Info
Company NameCHEMICAL COMPANY OF MALAYSIA BERHAD
Stock Name CCM   
Date Announced26 Dec 2012
CategoryNotice of Person Ceasing to be a Substantial Shareholder Pursuant to Form 29C of the Companies Act. 1965
Reference NoCC-121226-42862


本帖最后由 icy97 于 26-12-2012 10:07 PM 编辑

回复

使用道具 举报

发表于 26-12-2012 10:12 PM | 显示全部楼层

PNB以每股1.36的价位转换凭单,加上凭单当年的认购价为RM0.4522,
这样说来,PNB相信它每股应该值得RM1.8122。
为何EPF这一个多月抛售了近6百万股?
一个月跌了RM0.30,股价还会继续走低吗???
太玄了。。。。。 本帖最后由 xiaomao 于 27-12-2012 10:54 PM 编辑

回复

使用道具 举报

发表于 27-12-2012 12:10 AM | 显示全部楼层
xiaomao 发表于 26-12-2012 10:12 PM
@williamnkk81
PNB以每股1.36的价位转换凭单,加上凭单当年的认购价为RM0.4522,
这样说来,PNB相信它每 ...

股价还会不会。那就要看看EPF咯。。 是很低了。。。 但是业务不好。。。
回复

使用道具 举报

发表于 27-12-2012 10:55 PM | 显示全部楼层
williamnkk81 发表于 27-12-2012 12:10 AM
股价还会不会。那就要看看EPF咯。。 是很低了。。。 但是业务不好。。。

不好意思,无意间quote到你的nick...
业务不好= 亏钱??
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 注册

本版积分规则

 

ADVERTISEMENT



ADVERTISEMENT



ADVERTISEMENT

ADVERTISEMENT


版权所有 © 1996-2023 Cari Internet Sdn Bhd (483575-W)|IPSERVERONE 提供云主机|广告刊登|关于我们|私隐权|免控|投诉|联络|脸书|佳礼资讯网

GMT+8, 28-3-2024 08:46 PM , Processed in 0.074255 second(s), 22 queries , Gzip On.

Powered by Discuz! X3.4

Copyright © 2001-2021, Tencent Cloud.

快速回复 返回顶部 返回列表